Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06731894 · ClinicalTrials.gov registry record · Phase 2
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
A Phase 2 study of Breast Carcinoma and Chemotherapy-induced Peripheral Neuropathy, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT06731894 is a Phase 2 study of Breast Carcinoma and Chemotherapy-induced Peripheral Neuropathy that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 120 participants, below the 769-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06731894, a Phase 2 study of Breast Carcinoma and Chemotherapy-induced Peripheral Neuropathy, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \[CBD\] versus tetrahydrocannabinol \[THC\] and CBD formulation \[THC:CBD\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. Phytocannabinoids may be effective in reducing chronic chemotherapy-induced peripheral neuropathy symptoms in patients treated for breast or colon cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Cannabidiol
- OTHER Survey Administration
- DRUG Placebo Administration
- DRUG Dronabinol
Study Locations (2)
California
- City of Hope Medical Center - Duarte
- City of Hope at Irvine Lennar - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2028-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06731894
The ClinicalTrials.gov registry entry for NCT06731894 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 769-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (84% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06731894 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06731894 about?
NCT06731894 is a clinical study titled "Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors". This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \[CBD\] versus tetrahydrocannabinol \[THC\] and CBD formulation \[THC:CBD\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced perip...
What is the current status of trial NCT06731894?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-10-03. Estimated completion is 2028-01-07.
What conditions does trial NCT06731894 study?
This clinical trial studies the following conditions: Breast Carcinoma, Chemotherapy-induced Peripheral Neuropathy, Colon Carcinoma.
What interventions are being tested in trial NCT06731894?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Cannabidiol (DRUG), Survey Administration (OTHER), Placebo Administration (DRUG), Dronabinol (DRUG).
Who is sponsoring clinical trial NCT06731894?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06731894 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RECRUITING · Phase 2
-
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
RECRUITING · Phase 2
-
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
RECRUITING · Phase 2
-
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Breast Carcinoma
All registered trials for this condition
Chemotherapy-induced Peripheral Neuropathy
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.